Study explains how cancer drug triggers diabetes onset

04/3/2012 | International Business Times

Rapamycin, a drug used by organ transplant and cancer patients, appears to interact with the Yin Yang 1 gene and disrupt the insulin-signaling pathway in the liver and muscles, which results in the onset of diabetes in mice, researchers reported in Cell Metabolism. The findings suggest that rapamycin-treated patients may also want to take antidiabetes drugs that boost insulin sensitivity.

View Full Article in:

International Business Times

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY